[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cryoablation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cryoablation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,72,97,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":46,"locationsCount":49},"100640513","proximal-nerve-cryoablation-versus-perineuroma-cryoablation-for-chronic-neuroma-pain-after-combat-related-amputation-100640513",false,"NCT07618689","Proximal Nerve Cryoablation Versus Perineuroma Cryoablation for Chronic Neuroma Pain After Combat-Related Amputation","AXON-FREEZE","Inclusion Criteria:\n\n* Age ≥18 years\n* Combat-related limb amputation\n* Chronic neuroma pain lasting ≥3 months\n* Ultrasound-confirmed painful neuroma\n* Average pain intensity ≥4\u002F10 on Numeric Rating Scale\n* Positive Tinel sign\n* Ability to undergo ultrasound-guided cryoablation\n* Stable analgesic regimen for at least 14 days\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Active infection at the treatment site\n* Open wound preventing safe procedure\n* Previous cryoablation of the target nerve within 6 months\n* Neuroma surgery within 3 months\n* Severe coagulopathy or anticoagulation contraindicating procedure\n* Pregnancy or breastfeeding\n* Severe uncontrolled systemic disease\n* Inability to complete follow-up assessments","ALL","18 Years","60 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","atients with combat-related amputations frequently develop chronic neuroma pain that interferes with rehabilitation, prosthesis use, mobility, sleep, and quality of life. Cryoablation is a minimally invasive treatment that produces controlled nerve injury using extreme cold. Although the freezing effect is localized around the cryoprobe, axonal interruption followed by distal Wallerian degeneration may extend functional denervation distal to the ablation site.\n\nThis study aims to compare two ultrasound-guided cryoablation strategies for chronic neuroma pain after combat-related amputation: cryoablation performed directly near the neuroma and cryoablation performed proximal to the neuroma along the affected nerve.\n\nThe study will evaluate whether proximal nerve cryoablation produces greater or longer-lasting analgesic effects compared with perineuroma cryoablation.",[27,28],"Neuroma","Cryoablation",[28,30,31,32,33,34,35,36,37],"neuroma pain","combat-related amputation","phantom limb pain","residual limb pain","peripheral nerve injury","Wallerian degeneration","ultrasound-guided intervention","military trauma","NOT_YET_RECRUITING","2026-05-30",{"date":41,"type":42},"2026-06-02","ACTUAL",{"date":44,"type":21},"2026-10-15",{"date":44,"type":21},{"name":47,"class":48},"Ukrainian Society of Regional Anesthesia and Pain Therapy","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100615236","correlation-between-diagnostic-nerve-block-response-and-cryoneurolysis-outcome-in-chronic-musculoskeletal-disorders-100615236","NCT07289984","Correlation Between Diagnostic Nerve Block Response and Cryoneurolysis Outcome in Chronic Musculoskeletal Disorders","CRYONIC","Inclusion Criteria:\n\n* Be over 18 year old\n* Adults (\\> 18y) with either chronic musculoskeletal pain (\\> 3 months; average NRS \\> 5\u002F10) or painful\u002Ffunctionally limiting spasticity\n* Have a clinical stable condition, \\> 3months\n* Any medications must be maintained on a stable schedule- Able to understand study instructions and provide informed consent (ICF) in French or Dutch.Provide written informed consent\n\nExclusion Criteria:\n\n* Contraindication to cryoneurolysis such as a diagnosis of cryoglobulinemia, paroxysmal cold haemoglobinuria, cold urticaria, Raynaud's disease, any form of peripheral neuropathy, open and or infected wounds of the affected limb\n* Patient's refusal to give consent to the procedure or to use of their data for research purposes.\n* Ongoing local or systemic infection before the procedure.\n* Predominantly neuropathic pain of the upper extremity as assessed with the Pain Detect questionnaire",{"count":20,"type":21},[24],"The clinical study is titled the CRYONIC PROTOCOL, which stands for Cryotherapy for Neurolysis In Chronic Pain. It is structured as a prospective, multi-cohort observational study.\n\nPurpose of the Study:\n\nThe overarching purpose of the CRYONIC PROTOCOL study is to assess the Correlation Between Diagnostic Nerve Block Response and Cryoneurolysis Outcome in Chronic Musculoskeletal Disorders. The study focuses on evaluating the effectiveness of ultrasound-guided peripheral nerve cryoneurolysis, a minimally invasive technique that uses extreme cold to induce temporary nerve blocks, for patients with treatment-resistant chronic musculoskeletal pain.\n\nThe study also seeks to determine if cryoneurolysis itself leads to meaningful improvements in both pain intensity and functional ability in the included patient cohorts.",[61,62,28],"Chronic Musculoskeletal Pain","Cryo Analgesia","2026-04-21",{"date":65,"type":42},"2026-04-27",{"date":67,"type":21},"2026-07-01",{"date":69,"type":21},"2031-08-01",{"name":71,"class":48},"Universitair Ziekenhuis Brussel",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100633048","one-stop-diagnosis-and-treatment-for-suspected-lung-cancer-combined-rbs-ncle-obct-and-ablation-100633048","NCT07521618","One-stop Diagnosis and Treatment for Suspected Lung Cancer: Combined RBS, nClE, OBCT and Ablation","An Exploratory Clinical Trial on the Integration of Detection, Sampling and Treatment of Peripheral Lung Cancer by Robotic Bronchoscopy System","One-stop","Inclusion Criteria:\n\n* Age ≥18 years, male or female.\n* High-risk pulmonary nodule\u002Ftumor maximum diameter ≤3 cm.\n* Lesion judged suitable for bronchial navigation-guided diagnosis and treatment.\n* Ineligible for surgery or refuses surgery\u002Fradiotherapy; agrees to primary ablation therapy; provides written informed consent.\n\nExclusion Criteria:\n\n* Diffuse bilateral lung lesions unresponsive to ablation.\n* Contraindication to bronchoscopy or inability to tolerate\u002Fcooperate with bronchoscopy.\n* Severe bleeding tendency or irreversible coagulopathy (PT \\>18 s, PTA \\\u003C40%).Platelet count \\\u003C70×10⁹\u002FL; anticoagulant\u002Fantiplatelet therapy discontinued \\\u003C1 week before ablation (except prophylactic low-molecular-weight heparin).\n* Severe pulmonary impairment (maximal voluntary ventilation \\\u003C40%).\n* Other metastatic tumors with widespread metastasis; life expectancy \\\u003C3 months.\n* Poor general condition: widespread metastasis, severe infection, high fever, infectious\u002Fradiation inflammation around the lesion, obvious cachexia, severe organ dysfunction, severe anemia, uncorrectable metabolic\u002Fnutritional disorders.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\>2.\n* Target lesion received radiotherapy within the past 6 months.\n* Active hepatitis B, active hepatitis C, known HIV-1\u002F2 antibody positivity, or other active infections judged by the investigator to interfere with treatment.\n* History of epilepsy, psychosis, or cognitive impairment.\n* Pregnant\u002Flactating females; males or females planning conception during the trial.\n* Other conditions deemed inappropriate by the investigator.",{"count":81,"type":21},30,[24],"Using RBS as the navigation and treatment platform, precisely navigate to the target lesion. Utilize r-EUBS and nCLE to identify the lesion, and when the confocal AI model recognizes the lesion as malignant, perform a biopsy. Subsequently, under the guidance of OBCT, carry out ablation treatment of the lesion.",[85,28,86,87],"Lung Cancer (Suspected or Confirmed)","Robotic Bronchoscopy System","Confocal Laser Endomicroscopy","2026-04-08",{"date":90,"type":42},"2026-04-13",{"date":92,"type":21},"2026-04-01",{"date":94,"type":21},"2026-12-31",{"name":96,"class":48},"Guangzhou Medical University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":103,"targetDuration":105,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":49},"100341147","infant-and-child-european-cryoablation-project-icecap-100341147","NCT03721783","Infant and Child European Cryoablation Project ICECaP","Inclusion Criteria:\n\n* all children in whom a clinical decision is made to treat with percutaneous cryoablation, to include those in whom cryoablation was not technically or clinically possible at any stage.\n\nExclusion Criteria:\n\n* none",{"count":104,"type":21},40,"2 Years","OBSERVATIONAL","A registry to audit the current range of applications, technical success rate, safety profile, complication rate and efficacy of cryoablation procedures being performed in children.",[109,110,28,111],"Therapy","Soft Tissue Lesion","Pediatric",[113,114,115],"cryoablation","pediatric","registry","RECRUITING","2024-10-24",{"date":119,"type":42},"2024-10-26",{"date":121,"type":42},"2021-06-24",{"date":123,"type":21},"2027-07-01",{"name":125,"class":48},"Great Ormond Street Hospital for Children NHS Foundation Trust",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100536478","cryoablation-combined-with-cardonilizumab-and-bevacizumab-in-hepatocellular-carcinoma-with-pulmonary-metastases-100536478","NCT06265350","Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases","Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases: A Single-center, Prospective, Randomized Controlled Phase II Study","Inclusion Criteria:\n\n1. primary or recurrent HCC;\n2. synchronous metastases (within one month after diagnosing of HCC) or asynchronous metastases (more than one month after diagnosis of HCC);\n3. pulmonary-only metastases \\>5 and ≤10;\n4. metastases diameter ≤ 5 cm;\n5. intrahepatic tumors ≤5, and tumor burden ≤1\u002F2 liver volume;\n6. PVTT type Vp≤3;\n7. patients underwent first-line system therapy failure, the first-line system included tyrosine kinase inhibitor (TKI), such as Sorafenib or Lenvatinib, with or without PD-1 or PDL1 inhibitor;\n8. the intrahepatic tumors were effectively controlled and pulmonary metastases were no progression, and the controlled intrahepatic tumors were defined as partial or stable response according to modified Response Evaluation Criteria in Solid Tumors (mRECIST);\n9. locoregional therapy (including TACE or HAIC) were also included;\n10. Child-Pugh class A or B;\n11. PS 0 or 1;\n12. no history of other malignancies.\n\nExclusion Criteria:\n\n1. under 18 years or over 75 years;\n2. metastases \\>10\n3. non-lung metastases;\n4. incomplete clinical data;\n5. metastases diameter \\> 5 cm;\n6. intrahepatic tumors \\> 5, and tumor burden \\> 1\u002F2 liver volume;\n7. PVTT type Vp 4;\n8. lost to follow-up within 3 months.","75 Years",{"count":135,"type":21},80,[24],"This study intends to evaluate the efficacy and safety of cryoablation combined with Cardonilizumab and Bevacizumab in hepatocellular carcinoma with pulmonary metastases.",[139,140,141,142,143,28],"Hepatocellular Carcinoma","Liver Cancer Stage IV","Pulmonary Metastases","Cadonilimab","Bevacizumab","2024-02-09",{"date":146,"type":42},"2024-02-20",{"date":148,"type":42},"2024-02-02",{"date":150,"type":21},"2027-01-30",{"name":152,"class":48},"Sun Yat-sen University",2]